NO308034B1 - Nye aroylpiperidinderivater, farmasøytisk preparat inneholdende slike derivater og anvendelse derav - Google Patents

Nye aroylpiperidinderivater, farmasøytisk preparat inneholdende slike derivater og anvendelse derav

Info

Publication number
NO308034B1
NO308034B1 NO954067A NO954067A NO308034B1 NO 308034 B1 NO308034 B1 NO 308034B1 NO 954067 A NO954067 A NO 954067A NO 954067 A NO954067 A NO 954067A NO 308034 B1 NO308034 B1 NO 308034B1
Authority
NO
Norway
Prior art keywords
derivatives
new
aroylpiperidine
pharmaceutical preparations
preparations containing
Prior art date
Application number
NO954067A
Other languages
English (en)
Norwegian (no)
Other versions
NO954067D0 (no
NO954067L (no
Inventor
Silvio Ofner
Siem Jacob Veenstra
Walter Schilling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO954067D0 publication Critical patent/NO954067D0/no
Publication of NO954067L publication Critical patent/NO954067L/no
Publication of NO308034B1 publication Critical patent/NO308034B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Insulating Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Suspension Of Electric Lines Or Cables (AREA)
NO954067A 1994-10-14 1995-10-13 Nye aroylpiperidinderivater, farmasøytisk preparat inneholdende slike derivater og anvendelse derav NO308034B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH309194 1994-10-14

Publications (3)

Publication Number Publication Date
NO954067D0 NO954067D0 (no) 1995-10-13
NO954067L NO954067L (no) 1996-04-15
NO308034B1 true NO308034B1 (no) 2000-07-10

Family

ID=4248427

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954067A NO308034B1 (no) 1994-10-14 1995-10-13 Nye aroylpiperidinderivater, farmasøytisk preparat inneholdende slike derivater og anvendelse derav

Country Status (23)

Country Link
US (1) US5965562A (fi)
EP (1) EP0707006B1 (fi)
JP (1) JP3022951B2 (fi)
KR (1) KR100413985B1 (fi)
CN (1) CN1066445C (fi)
AT (1) ATE178602T1 (fi)
AU (1) AU705851B2 (fi)
CA (1) CA2160444C (fi)
DE (1) DE59505575D1 (fi)
DK (1) DK0707006T3 (fi)
ES (1) ES2132580T3 (fi)
FI (1) FI114795B (fi)
GR (1) GR3030515T3 (fi)
HU (1) HUT74103A (fi)
IL (1) IL115572A (fi)
MX (1) MX9504349A (fi)
MY (1) MY114679A (fi)
NO (1) NO308034B1 (fi)
NZ (1) NZ280212A (fi)
RU (1) RU2158731C2 (fi)
SA (1) SA96160637B1 (fi)
TW (1) TW397825B (fi)
ZA (1) ZA958647B (fi)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
TW475930B (en) * 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
WO1997045119A1 (en) * 1996-05-24 1997-12-04 Novartis Ag Use of substance p antagonists for treating social phobia
AR018376A1 (es) * 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
DE69907220T2 (de) * 1998-08-25 2004-02-05 Novartis Ag Verwendung von substanz p antagonisten zur behandlung des chronischen ermüdungssyndroms und/oder der fibromyalgie
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
ATE387429T1 (de) 1999-11-03 2008-03-15 Amr Technology Inc Arly- und heteroaryl-substituierte tetrahydroisoquinoline und ihre verwendung als hemmer der wiederaufnahme von norepinephrin, dopamin und serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
JP2001294582A (ja) * 2000-04-12 2001-10-23 Fuji Chemical Industries Ltd 光学活性アミノブチロラクトンの製造法
EP1299393A2 (en) 2000-07-11 2003-04-09 Bristol-Myers Squibb Pharma Company 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
GB0220953D0 (en) 2002-09-10 2002-10-23 Novartis Ag Organic compounds
GB2394417A (en) * 2002-10-24 2004-04-28 Novartis Ag Solid dispersion comprising a piperidine substance P antagonist and a carrier
WO2004094380A1 (en) 2003-04-18 2004-11-04 Eli Lilly And Company (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists
CA2573271C (en) 2004-07-15 2015-10-06 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
BRPI0613403A2 (pt) 2005-07-15 2009-02-10 Amr Technology Inc tetrahidrobenzodiazepinas aril- e heteroarila-substituÍdas e uso das mesmas para bloquear a recaptaÇço de norepinefrina, dopamina e serotonina
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2336120B1 (en) 2007-01-10 2014-07-16 MSD Italia S.r.l. Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
ES2662072T3 (es) 2009-05-12 2018-04-05 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
KR101485645B1 (ko) 2009-10-14 2015-01-22 머크 샤프 앤드 돔 코포레이션 ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
EP4079856A1 (en) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
SI2925888T1 (en) 2012-11-28 2018-02-28 Merck Sharp & Dohme Corp. Compounds and methods for the treatment of cancer
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN111808017B (zh) * 2020-08-05 2023-11-28 国家纳米科学中心 一种含氮杂环化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5145967A (en) * 1989-04-20 1992-09-08 Anaquest, Inc. Method for preparing 4-alkoxyalkyl-4-phenylaminopiperdines and derivatives thereof
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5126455A (en) * 1989-12-13 1992-06-30 Glaxo Inc. Preparation of substituted alkali metal piperidine-4-carboxylates
PL169187B1 (pl) * 1990-05-31 1996-06-28 Pfizer Sposób wytwarzania podstawionych piperydyn PL PL PL
DK0532527T3 (da) * 1990-06-01 1995-01-02 Pfizer 3-amino-2-arylquinuclidiner, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse
JPH0772175B2 (ja) * 1990-09-28 1995-08-02 フアイザー・インコーポレイテツド 窒素含有非芳香族複素環の縮合環類似体
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives

Also Published As

Publication number Publication date
FI954829A (fi) 1996-04-15
KR100413985B1 (ko) 2004-03-26
MY114679A (en) 2002-12-31
JPH08176145A (ja) 1996-07-09
EP0707006A1 (de) 1996-04-17
IL115572A0 (en) 1996-01-19
EP0707006B1 (de) 1999-04-07
CN1133839A (zh) 1996-10-23
RU2158731C2 (ru) 2000-11-10
NZ280212A (en) 2001-10-26
CN1066445C (zh) 2001-05-30
MX9504349A (es) 1997-03-29
HUT74103A (en) 1996-11-28
TW397825B (en) 2000-07-11
AU705851B2 (en) 1999-06-03
IL115572A (en) 2001-05-20
NO954067D0 (no) 1995-10-13
KR960014121A (ko) 1996-05-22
ZA958647B (en) 1996-04-15
DE59505575D1 (de) 1999-05-12
GR3030515T3 (en) 1999-10-29
AU3317495A (en) 1996-04-26
FI114795B (fi) 2004-12-31
CA2160444C (en) 2006-11-28
NO954067L (no) 1996-04-15
US5965562A (en) 1999-10-12
HU9502973D0 (en) 1995-12-28
ES2132580T3 (es) 1999-08-16
ATE178602T1 (de) 1999-04-15
FI954829A0 (fi) 1995-10-11
SA96160637B1 (ar) 2005-06-14
JP3022951B2 (ja) 2000-03-21
CA2160444A1 (en) 1996-04-15
DK0707006T3 (da) 1999-10-18

Similar Documents

Publication Publication Date Title
NO308034B1 (no) Nye aroylpiperidinderivater, farmasøytisk preparat inneholdende slike derivater og anvendelse derav
DE3879264D1 (de) N-substituierte azole.
DE69506510T2 (de) Piperidinderivate, verwendbar als Neurokinin-Rezeptor-Antagonisten
DK252286D0 (da) Amidderivater af quinolin, fremgangsmaade til deres fremstilling og laegemidler indeholdende disse forbindelser
DK0481522T3 (da) Nye mercaptoacetylamid-derivater anvendelige som inhibitorer af enkephalinase og ACE
BR9803295A (pt) preparos e composições farmacêuticas contendo os mesmos.
AR009212A1 (es) Un derivado de 3-piperidil-4-oxoquinazolina; una composicion farmaceutica, un inhibidor de la proteina de transferencia de los trigliceridos microsomal(mtp) y un agente terapeutico o preventivo para la hiperlipemia o la arteriosclerosis que lo contienen
DK0662471T3 (da) Naphthalenderivater med affinitet over for melatonin-receptorer, fremgangsmåde til deres fremstilling og farmaceutiske samm
NO305174B1 (no) Heterocykliske forbindelser
DK0461958T3 (da) 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i terapien
DK0717036T3 (da) Anvendelse af 5-acyl-1,4-dihydropyridiner til bekæmpelse af sygdomme i CNS
DE59507220D1 (de) Verwendung von 1,2-überbrückten 1,4-Dihydropyridinen als selektive Kaliumkanalmodulatoren
DE59505429D1 (de) Alkyl-5-methylsulfonyl-benzoyl-guanidin-Derivate
NO972943D0 (no) 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende disse forbindelsene og deres anvendelse
NO304314B1 (no) Cykloheksanderivater og anvendelse av forbindelsene for fremstilling av legemidler
DK283189D0 (da) Phenothiazinderivater, deres fremstilling og farmaceutiske praeparater deraf
DK0713865T3 (da) Derivater af 2-aminobenzensulfonsyre og 2-aminobenzensulfonylchlorid, fremstilling og anvendelse heraf som syntesemellempro
DK0512522T3 (da) Nye antibiotiske forbindelser og deres fremstilling
DK30086D0 (da) 5-aryl-dihydropyridiner, deres fremstilling og anvendelse i laegemidler
DK0582506T3 (da) Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf og terapeutisk anvendelse af disse
DK0816359T3 (da) 4-amino-2-ureido-pyrimidin-5-carboxylsyreamider, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
ECSP951529A (es) Compuestos farmaceuticos
NO941830D0 (no) Karboksamid-derivater, deres fremstilling og anvendelse som terapeutika
DE60239284D1 (de) Azotierte tetrahydropyridyl-alkyl-heterozyklen mit tnf-wirkung
ATE17490T1 (de) Dithiino (1,4) (2,3-c) pyrrolderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees